{"product_id":"heart-in-diabetes-9th-annual-heart-in-diabetes-conference-2025","title":"Heart in Diabetes 9th Annual Heart in Diabetes Conference 2025","description":"\u003cdiv class=\"prod-edition\"\u003e\r\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\r\n\u003cdiv class=\"columns small-12 medium-12 large-12 sidebar-full\"\u003e\r\n\u003cdiv class=\"elementor-element elementor-element-bbb44b8 elementor-widget elementor-widget-heading\" data-id=\"bbb44b8\" data-element_type=\"widget\" data-widget_type=\"heading.default\"\u003e\r\n\u003cdiv class=\"bundle--paragraph_component paragraph paragraph--type--paragraph-component paragraph--view-mode--default\"\u003e\r\n\u003ch1 class=\"product_title entry-title\"\u003eHeart in Diabetes 9th Annual Heart in Diabetes Conference 2025\u003c\/h1\u003e\r\n\u003cstrong\u003e+ Include: 72 Videos (.mp4) + 72 Audios (.mp3) + 72 Subtitles (.vtt) + 57 PDFs, size: 32.09 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Target Audience: cardiologists, endocrinologists, and nephrologists\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\r\n\u003ch2 data-path-to-node=\"0\"\u003e1. Overview\u003c\/h2\u003e\r\n\u003cp data-path-to-node=\"1\"\u003eThe Heart in Diabetes 9th Annual Conference 2025 provides a comprehensive clinical exploration of the intersection between cardiovascular, renal, and metabolic diseases. The program delivers expert insights into managing resistant hypertension, chronic kidney disease, heart failure, obesity, and dyslipidemia, emphasizing the latest pharmacological advancements such as GLP-1 receptor agonists, SGLT2 inhibitors, and novel lipid-lowering therapies.\u003c\/p\u003e\r\n\u003cp data-path-to-node=\"1\"\u003e\u003cb data-path-to-node=\"1\" data-index-in-node=\"450\"\u003eCourse Date:\u003c\/b\u003e 2025\u003c\/p\u003e\r\n\r\n\u003ch2 data-path-to-node=\"2\"\u003e2. Learning Objectives\u003c\/h2\u003e\r\n\u003cul data-path-to-node=\"3\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"3,0,0\"\u003eEvaluate the pathophysiology and clinical management of cardiorenal metabolic diseases, including resistant hypertension and diabetic cardiomyopathy.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"3,1,0\"\u003eImplement guideline-directed medical therapies using GLP-1 RAs, SGLT2 inhibitors, and novel MRAs to optimize cardio-renal protection in patients with diabetes.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"3,2,0\"\u003eAnalyze the systemic impact of sleep disorders, hypercortisolism, and women-specific risk factors on cardiovascular and metabolic health.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"3,3,0\"\u003eAssess the latest cardiovascular outcome trials (CVOTs) and integrate emerging lipid-lowering treatments targeting ApoB and CETP into clinical practice.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"3,4,0\"\u003eApply digital health technologies, intensive lifestyle interventions, and multidisciplinary approaches to manage complex cases involving obesity and heart failure.\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-path-to-node=\"4\"\u003e3. Target Audience\u003c\/h2\u003e\r\nBest for cardiologists, endocrinologists, and nephrologists who want updates on cardiorenal metabolic therapies, clinical trials, and obesity.\r\n\u003ch2 data-path-to-node=\"6\"\u003e4. Topics\u003c\/h2\u003e\r\n\u003cul data-path-to-node=\"8\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,0,0\"\u003eDay 1 01 Epidemiology and Pathophysiology of Resistant Hypertension and CKD Treatment\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,1,0\"\u003eDay 1 02 Management of Chronic Kidney Disease With or Without Albuminuria\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,2,0\"\u003eDay 1 03 Emerging Approaches to the Treatment of Resistant Hypertension\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,3,0\"\u003eDay 1 04 Case Presentation – Treatment Resistant Hypertension\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,4,0\"\u003eDay 1 05 Cortisol – Impact on Endocrinology \u0026amp; Metabolism\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,5,0\"\u003eDay 1 06 Cortisol’s Impact on the Kidney-BP-Bone\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,6,0\"\u003eDay 1 07 Cardiovascular Implications of Hypercortisolism\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,7,0\"\u003eDay 1 08 Panel Discussion and Q\u0026amp;A – Cortisol \u0026amp; Cardiorenalmetabolic Diseases\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,8,0\"\u003eDay 1 09 MASLD and MASH – Pathophysiology, Diagnosis and Management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,9,0\"\u003eDay 1 10 Sleep Health – Implications for Obesity and Diabetes Risk\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,10,0\"\u003eDay 1 11 Sleep and Cardiovascular Risk\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,11,0\"\u003eDay 1 12 Panel Discussion and Q\u0026amp;A – Sleep Disorders in Cardiometabolism\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,12,0\"\u003eDay 1 13 Prediabetes – What’s a Clinician to Do\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,13,0\"\u003eDay 1 14 Unraveling the Connection – Diabetes and Dementia\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,14,0\"\u003eDay 1 15 Pulmonary Disorders in Diabetes – Implications for Heart Disease\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,15,0\"\u003eDay 1 16 Diabetes and Cardiovascular Disease in Older Adults\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,16,0\"\u003eDay 1 17 Panel Discussion and Q\u0026amp;A – Diabetes Comorbidities\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,17,0\"\u003eDay 1 18 Implementing Guideline-Directed Medical Therapy – Stakeholder-Identified Barriers and Facilitators\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,18,0\"\u003eDay 1 19 Population Health Approaches to Accelerate the Prevention of CVD – Moving from Action to Impact\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,19,0\"\u003eDay 1 20 Panel Discussion and Q\u0026amp;A – Implementation Science in Practice\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,20,0\"\u003eDay 1 21 Dyslipidemia in Women Across a Lifetime Approach to Management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,21,0\"\u003eDay 1 22 Sex Hormones and Anthropometric Measures \u0026amp; Heart Failure Risk in Women\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,22,0\"\u003eDay 1 23 Panel Discussion and Q\u0026amp;A – Women’s Health\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,23,0\"\u003eDay 1 24 Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone or In Combination With SGLT2 Inhibit…\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,24,0\"\u003eDay 1 25 Optimal Strategy for Heart Failure Screening Among Adults With Diabetes Without ASCVD – A Pooled Cohort Analysis\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,25,0\"\u003eDay 1 26 Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibro…\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,26,0\"\u003eDay 1 27 Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Chronic Kidney Disease\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,27,0\"\u003eDay 1 28 Panel Discussion and Q\u0026amp;A – Circulation\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,28,0\"\u003eDay 2 01 Current Trends in Epidemiology of Heart Failure – USA\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,29,0\"\u003eDay 2 02 Diabetic Cardiomyopathy – Mechanisms and Future Directions\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,30,0\"\u003eDay 2 03 Bromocriptine in the Treatment of Peripartum Cardiomyopathy – Is It Ready for Prime Time\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,31,0\"\u003eDay 2 04 Proper Medical Management of HFpEF in 2025\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,32,0\"\u003eDay 2 05 Panel Discussion and Q\u0026amp;A – Heart Failure – The Now \u0026amp; The New\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,33,0\"\u003eDay 2 06 GLP1-RA, Obesity \u0026amp; Diabetes – Mechanisms of Cardiovascular Protection\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,34,0\"\u003eDay 2 07 Cardio-Kidney Protection With Incretin Therapies\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,35,0\"\u003eDay 2 08 Incretins – Today and Tomorrow\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,36,0\"\u003eDay 2 09 Panel Discussion and Q\u0026amp;A – Current \u0026amp; Future Role of Incretin Therapy\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,37,0\"\u003eDay 2 10 Diabetes and Cardiovascular Disease – The Evolution of CV Outcomes Assessment of Antihyperglycemic Medications\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,38,0\"\u003eDay 2 11 My Personal Journey to HoFH Diagnosis\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,39,0\"\u003eDay 2 12 From Rare to the Very Common – Role of Genetics in Lipid Disorders\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,40,0\"\u003eDay 2 13 CETPi – Where Might They Fit Into Clinical Practice\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,41,0\"\u003eDay 2 14 Using ApoB in Clinical Practice – From Risk Assessment to Treatment Targets\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,42,0\"\u003eDay 2 15 Obesity and Dyslipidemia – Can We Finally Break the Cycle With Dual Agonists\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,43,0\"\u003eDay 2 16 The Epidemiology and Pathophysiology of Cardio-Kidney-Metabolic Diseases\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,44,0\"\u003eDay 2 17 Unmet Needs in CKD in T1D and Challenges in CKD Beyond Diabetes\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,45,0\"\u003eDay 2 18 Finerenone Across the Stages of Heart Failure – From Prevention to Treatment\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,46,0\"\u003eDay 2 19 Panel Discussion and Q\u0026amp;A – Cardio-Renal Protection in CKM Diseases\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,47,0\"\u003eDay 2 20 Digital Health Technologies for Cardiometabolic Disease \u0026amp; Diabetes\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,48,0\"\u003eDay 2 21 Food Is Medicine Strategies for Nutrition Security \u0026amp; Cardiometabolic Health Equity – JACC State-of-the-Art Review\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,49,0\"\u003eDay 2 22 Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes – The Look AHEAD Cardiac…\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,50,0\"\u003eDay 2 23 Racial Differences in Diabetic Cardiomyopathy – Results From the Phase 3 Randomized Controlled ARISE-HF Study\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,51,0\"\u003eDay 2 24 Panel Discussion and Q\u0026amp;A – JACC\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,52,0\"\u003eDay 2 25 Technology in the Management of Diabetes – Addressing Its Role in Comorbidities\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,53,0\"\u003eDay 2 26 SGLT2 Inhibitors – Reconsidering, Repurposing, Reimagining\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,54,0\"\u003eDay 2 27 Panel Discussion and Q\u0026amp;A – Diabetes Management \u0026amp; Technology\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,55,0\"\u003eDay 3 01 Management of Complex Cases – Obesity and Heart Failure\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,56,0\"\u003eDay 3 02 The Edema Dilemma – A Case of Diabetes Mellitus, Heart Failure With Preserved Ejection Fraction, Obesity, Chronic Kidne…\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,57,0\"\u003eDay 3 03 CRM Management of Complex Cases\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,58,0\"\u003eDay 3 04 The Lancet Commission on Obesity\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,59,0\"\u003eDay 3 05 Obesity – Role of Medical Management\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,60,0\"\u003eDay 3 06 Management of Obesity Addressing Lean Mass Preservation\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,61,0\"\u003eDay 3 07 Panel Discussion and Q\u0026amp;A – Obesity\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,62,0\"\u003eDay 3 08 Do ACEiARB Still Have a Role in the Era of SGLT2, MRA and GLP1A\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,63,0\"\u003eDay 3 09 The Role of Diastolic \u0026amp; Pulse Pressure in CKD \u0026amp; CVD – Management Considerations\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,64,0\"\u003eDay 3 10 Aldosterone – The Forgotten Hormone in Hypertension\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,65,0\"\u003eDay 3 11 Panel Discussion and Q\u0026amp;A – The Kidney and Hypertension\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,66,0\"\u003eDay 3 12 Combination Treatment to Improve Heart and Kidney Outcomes in Diabetic Kidney Disease\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,67,0\"\u003eDay 3 13 The Latest Heart Disease \u0026amp; Stroke Statistics – US \u0026amp; Global Data from the American Heart Association\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,68,0\"\u003eDay 3 14 Appropriate Cardiac Intervention in the Diabetes Cardiorenal \u0026amp; Metabolic Medicine Patient\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,69,0\"\u003eDay 3 15 Serum Lipoproteins \u0026amp; Coronary Atherosclerosis in Asymptomatic U.S. Adults Without Traditional Risk Factors\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,70,0\"\u003eDay 3 16 Cardiovascular Outcome Trials Update\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,71,0\"\u003eDay 3 17 Panel Discussion and Q\u0026amp;A – ASCVD\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954561028194,"sku":"MED-AMB06106","price":30.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Heart-in-Diabetes-9th-Annual-Heart-in-Diabetes-Conference-2025.jpg?v=1779379731","url":"https:\/\/meducourse.com\/products\/heart-in-diabetes-9th-annual-heart-in-diabetes-conference-2025","provider":"Meducourse","version":"1.0","type":"link"}